FDA stalls decision on petition to suspend mRNA injections, citing ‘other priorities’

The US regulator quietly delays action on a petition calling for the suspension of mRNA injections—despite evidence of regulatory failure, DNA contamination, and a surge in cancers among young people.

The U.S. Food and Drug Administration (FDA) has delayed its response to a formal petition demanding the suspension of the mRNA Covid-19 injections, citing “the existence of other FDA priorities.”

In a letter dated 17 July 2025, Dr Vinay Prasad—recently appointed Director of the FDA’s Center for Biologics Evaluation and Research (CBER)—acknowledged that the agency had “not yet reached resolution of the issues raised” in the petition.

Filed on 20 January 2025, the petition alleges that Pfizer’s Comirnaty and Moderna’s Spikevax were “unlawfully approved” in violation of federal regulatory requirements.

It calls for an immediate halt to the injections, independent testing of retained vials, and a full investigation into the approval process.